MeiraGTx (MGTX) Chardan’s 9th Annual Genetic Medicines Conference summary

Program overviews and recent milestones

• Companies focus on gene therapies for neurodegenerative diseases, emphasizing local delivery and in-house manufacturing to improve safety and reduce costs.

• Recent milestones include pivotal studies in eye diseases and Parkinson’s, with BLA filings pending and partnerships leveraging AI for data analysis.

• Huntington’s disease program showed 75% slowing of disease progression and significant biomarker improvements, with a BLA submission planned next year.

• Frontotemporal dementia program demonstrated high target engagement and biomarker stabilization, with further data expected next year.

Key challenges in gene therapy for neurodegenerative diseases

• Delivery to the correct brain region remains a major challenge, especially for diseases like Huntington’s.

• Slow disease progression complicates clinical trial design and endpoint measurement.

• Local delivery and targeting specific brain nuclei can address both efficacy and safety concerns.

• AI and advanced analytics are being used to address patient heterogeneity and improve endpoint robustness.

Addressing heterogeneity and trial design

• AI models trained on extensive clinical data can distinguish true physiological changes from patient variability.

• Propensity score matching and external controls help reduce bias in small patient populations.

• Regulatory agencies are increasingly open to novel endpoints and trial designs, especially for rare diseases with high unmet need.